Newsroom

Sorted by: Latest

-

Hisense se suma al consorcio de patentes HEVC Advance

BOSTON--(BUSINESS WIRE)--Access Advance LLC, líder mundial en licencias de consorcios de patentes de códecs de vídeo, ha anunciado hoy que Hisense Group Holdings Co., Ltd. se ha incorporado al consorcio de patentes HEVC Advance en calidad de licenciatario. Hisense se suma a las incorporaciones recientes al consorcio de patentes de Access Advance, entre las que se destacan Xiaomi, MSI y Transsion, y amplía sus relaciones con Huawei, HP y Sharp. Hisense, con sede en Qingdao (China), es uno de los...
-

Hisense voegt zich bij HEVC Advance Patent Pool

BOSTON--(BUSINESS WIRE)--Access Advance LLC, de wereldwijde leider in licentieverlening voor patentpools voor videocodecs, heeft vandaag aangekondigd dat Hisense Group Holdings Co., Ltd. zich bij de HEVC Advance Patent Pool heeft gevoegd als licentienemer. Hisense voegt zich bij de recente toevoegingen aan de patentpools van Access Advance, waaronder Xiaomi, MSI, Transsion, en de uitgebreide samenwerkingen met Huawei, HP en Sharp. Hisense, met hoofdkantoor in Qingdao, China, is een van 's werel...
-

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

TOKYO--(BUSINESS WIRE)--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma...
-

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

TOKYO--(BUSINESS WIRE)--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer...
-

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer...
-

Rapport de couverture analyste de GBC AG sur Mexedia S.p.A. Società Benefit finalisé et publié

ROME--(BUSINESS WIRE)--Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris : ALMEX, ISIN IT0005450819) (« Mexedia » ou la « Société ») informe que le rapport de couverture analyste préparé par GBC AG – l’un des principaux cabinets indépendants de recherche financière en Allemagne –, élaboré dans le cadre d’une issuer-sponsored research, a été finalisé et est désormais publiquement disponible. Ce rapport fait suite à la reprise de la couverture analyste par GBC AG, précédemmen...
-

Completato e pubblicato il report di analyst coverage di GBC AG su Mexedia S.p.A. Società Benefit

ROMA--(BUSINESS WIRE)--Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” o la “Società”) comunica che il report di analyst coverage predisposto da GBC AG – una delle principali società indipendenti di ricerca finanziaria in Germania –, sviluppato nell’ambito di un contesto di issuer-sponsored research, è stato completato ed è ora pubblicamente disponibile. Il report fa seguito alla riattivazione della copertura da parte di GBC AG, precedentemente comuni...
-

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published

ROME--(BUSINESS WIRE)--Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and...
-

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer...
-

Nanhua Singapore成為ICE Futures Singapore和ICE Clear Singapore的交易所及結算會員

新加坡--(BUSINESS WIRE)--(美國商業資訊)-- 全球首屈一指的技術和資料供應商Intercontinental Exchange (NYSE:ICE)今日宣布,Nanhua Singapore Pte. Ltd. (Nanhua Singapore)已正式成為ICE Futures Singapore和ICE Clear Singapore的會員。憑藉這一雙重會員資格,Nanhua Singapore可展開自營業務和客戶業務的交易及結算操作。 Nanhua Singapore執行長Zheng Peiyuan表示:「我們欣然加入新加坡的ICE平台,成為會員後,Nanhua Singapore得以強化自身的交易和全球結算能力,為客戶擴大國際市場的投資機會。這一會員資格彰顯了我們對於提供可靠高效的服務、滿足客戶不斷變化的需求的承諾,我們期待在持續協助客戶實現全球業務成長的同時,深化與ICE的合作。」 ICE Futures Singapore和ICE Clear Singapore總裁兼營運長Maria Levanti表示:「我們欣然歡迎Nanhua Singapore加入...